Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Pharvaris (PHVS)
NASDAQ:PHVS
Holding PHVS?
Track your performance easily
PHVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$15.21 - $33.00
Previous CloseN/A
Volume14.65K
Average Volume (3M)53.47K
Market Cap
$1.01B
Enterprise Value$660.90M
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Apr 24, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.68
Shares Outstanding54,007,710
10 Day Avg. Volume60,048
30 Day Avg. Volume53,472
Standard Deviation0.68
R-Squared0.04
Alpha0.10
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market Cap0.65
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-32.02
Forecast
1Y Price Target
$33.40Price Target Upside89.34% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
Pharvaris News
PremiumCompany Announcements
Pharvaris Sets 2025 Strategic Priorities in HAE and AAE Treatments
PremiumCompany Announcements
Pharvaris Reports Q3 2024 Progress and Financials
PremiumCompany Announcements
Pharvaris Advances in HAE Treatment with Strong Financials
Bulls Say, Bears Say
Bulls Say
Market OpportunityDeucrictibant's differentiated profile could drive blockbuster sales despite the entrenched competition in hereditary angioedema.
Patient AdoptionDeucrictibant is far easier to administer than an icatibant injection in the setting of an acute attack, which could result in significant market share gain.
Safety And EfficacyPharvaris' oral deucrictibant has promising efficacy and safety in hereditary angioedema, both as an on-demand therapy for acute attacks and in long-term prophylactic settings.
Bears Say
Clinical DataClinical updates are largely incremental, awaiting additional data before revisiting the valuation model.
Financial PerformanceAnalyst maintains Underperform rating with a $14 price objective.
Market ChallengesUp to 5% of US patients actively switch therapies every quarter, highlighting challenges with switching therapies.
---
Ownership Overview
―
Insiders
7.25% Mutual Funds
71.83% Other Institutional Investors
20.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PHVS FAQ
What was Pharvaris’s price range in the past 12 months?
Pharvaris lowest stock price was $15.21 and its highest was $33.00 in the past 12 months.
What is Pharvaris’s market cap?
Pharvaris’s market cap is $1.01B.
When is Pharvaris’s upcoming earnings report date?
Pharvaris’s upcoming earnings report date is Apr 24, 2025 which is in 83 days.
How were Pharvaris’s earnings last quarter?
Pharvaris released its earnings results on Nov 13, 2024. The company reported -$0.802 earnings per share for the quarter, missing the consensus estimate of -$0.617 by -$0.185.
Is Pharvaris overvalued?
According to Wall Street analysts Pharvaris’s price is currently Undervalued.
Does Pharvaris pay dividends?
Pharvaris does not currently pay dividends.
What is Pharvaris’s EPS estimate?
Pharvaris’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharvaris have?
Pharvaris has 54,007,710 shares outstanding.
What happened to Pharvaris’s price movement after its last earnings report?
Pharvaris reported an EPS of -$0.802 in its last earnings report, missing expectations of -$0.617. Following the earnings report the stock price went up 2.545%.
Which hedge fund is a major shareholder of Pharvaris?
Currently, no hedge funds are holding shares in PHVS
---
Pharvaris Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$33.40 (89.34% Upside)
$33.40 (89.34% Upside)
Hedge Fund Trend
Increased
By 634.4K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.46%
12-Months-Change
Fundamentals
Return on Equity
-58.16%
Trailing 12-Months
Asset Growth
94.95%
Trailing 12-Months
Company Description
Pharvaris
Pharvaris NV is a clinical-stage company. It is focused on the discovery and development of novel oral bradykinin B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin B2-receptor-mediated indications.
---
PHVS Stock 12 Month Forecast
Average Price Target
$33.40
▲(89.34% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
AnaptysBio
―
Kiniksa Pharmaceuticals
―
Akero Therapeutics
―
Arcutis Biotherapeutics
―
Best Analysts Covering PHVS
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
+57.85%
reiterated a buy rating 2 months ago
Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +57.85% per trade.
---